Literature DB >> 7016969

Glucagon and carbohydrate disorder in a totally pancreatectomized man (a study with the aid of an artificial endocrine pancreas).

F Santeusanio, M Massi-Benedetti, G Angeletti, G Calabrese, A Bueti, P Brunetti.   

Abstract

The effect of insulin withdrawal and exogenous glucagon infusion upon blood glucose concentration was investigated in a totally pancreatectomized patient with the aid of an artificial endocrine pancreas. Blood glucose remained unchanged at about 100 mg/100 ml, when insulin infusion was stopped, but rose up to 300 mg/100 ml, during a 12-h period of exogenous glucagon infusion at a rate of 3 ng/kg/min. Fractionation of whole plasma on Bio Gel P-30 revealed no immunoreactive glucagon in the region of true glucagon. This study seems to reinforce the hypothesis that true glucagon is essential in the fasting condition at least in the short term to produce hyperglycemia in insulin deprived diabetics.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7016969     DOI: 10.1007/BF03349422

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

1.  Presence of glucagon immunoreactivity in the globulin fraction of human plasma ("big plasma glucagon").

Authors:  I Valverde; M L Villanueva; I Lozano; J Marco
Journal:  J Clin Endocrinol Metab       Date:  1974-12       Impact factor: 5.958

2.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

3.  Factors controlling gastric-glucagon release.

Authors:  P J Lefèbvre; A S Luyckx
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

4.  Plasma glucagon after total resection of the pancreas in man.

Authors:  M Miyata; T Yamamoyo; M Yamaguchi; K Nakao; T Yoshida
Journal:  Proc Soc Exp Biol Med       Date:  1976-09

5.  Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.

Authors:  J E Gerich; M Lorenzi; D M Bier; V Schneider; E Tsalikian; J H Karam; P H Forsham
Journal:  N Engl J Med       Date:  1975-05-08       Impact factor: 91.245

6.  Properties of immunoreactive glucagon fractions of canine stomach and pancreas.

Authors:  C B Srikant; K McCorkle; R H Unger
Journal:  J Biol Chem       Date:  1977-03-25       Impact factor: 5.157

7.  Glucagon immunoreactivities and amino acid profile in plasma of duodenopancreatectomized patients.

Authors:  W A Muller; M Berger; P Suter; H J Cüppers; J Reiter; T Wyss; P Berchtold; F H Schmidt; J P Assal; A E Renold
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

8.  Identical biological effects of pancreatic glucagon and a purified moiety of canine gastric immunoreactive glucagon.

Authors:  K Doi; M Prentki; C Yip; W A Muller; B Jeanrenaud; M Vranic
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

9.  The essential role of glucagon in the pathogenesis of diabetes mellitus.

Authors:  R H Unger; L Orci
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

10.  Role of glucagon and other hormones in development of diabetic ketoacidosis.

Authors:  K G Alberti
Journal:  Lancet       Date:  1975-06-14       Impact factor: 79.321

View more
  2 in total

Review 1.  Glucagon physiology and pathophysiology in the light of new advances.

Authors:  R H Unger
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

2.  Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats.

Authors:  C L Brand; B Rolin; P N Jørgensen; I Svendsen; J S Kristensen; J J Holst
Journal:  Diabetologia       Date:  1994-10       Impact factor: 10.122

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.